{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:47:27Z","timestamp":1782780447746,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002039","name":"CURE Childhood Cancer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000885","name":"Children's Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000885","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013187","name":"Randy Shaver Cancer Research & Community Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013187","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omta.2026.201734","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:54:14Z","timestamp":1775757254000},"page":"201734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficient, fratricide free non-viral engineering of CD70-targeted CAR NK cells for hematologic and solid tumor immunotherapy"],"prefix":"10.1016","volume":"34","author":[{"given":"Jae-Woong","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7658-149X","authenticated-orcid":false,"given":"Joshua","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Folsom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Skeate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walker S.","family":"Lahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Slipek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J.","family":"Pomeroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beau R.","family":"Webber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branden S.","family":"Moriarity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201734_bib1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.gde.2018.06.003","article-title":"Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system","volume":"52","author":"Hudecek","year":"2018","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.omta.2026.201734_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1186\/s12967-022-03747-3","article-title":"Current strategies employed in the manipulation of gene expression for clinical purposes","volume":"20","author":"Tsai","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omta.2026.201734_bib3","first-page":"E478","article-title":"A resurrected mammalian hAT transposable element and a closely related insect element are highly active in human cell culture","volume":"110","author":"Li","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201734_bib4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.ymthe.2024.04.024","article-title":"Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies","volume":"32","author":"Skeate","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201734_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009560","article-title":"Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing","volume":"13","author":"Wang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omta.2026.201734_bib6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201734_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/14712598.2022.2154601","article-title":"CAR-NK cells: a promising cellular immunotherapy in lymphoma","volume":"23","author":"Khanmohammadi","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omta.2026.201734_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.19.1.197","article-title":"Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis","volume":"19","author":"Moretta","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omta.2026.201734_bib9","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-specific CAR-NK cells expressing IL-15 for the treatment of CD19-negative B cell malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201734_bib10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-022-00660-2","article-title":"Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia","volume":"12","author":"Albinger","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omta.2026.201734_bib11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2020.271908","article-title":"CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide","volume":"107","author":"Gurney","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.omta.2026.201734_bib12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","article-title":"Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia","volume":"15","author":"Caruso","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omta.2026.201734_bib13","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.omta.2026.201734_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cac2.12394","article-title":"Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors","volume":"43","author":"Ghaedrahmati","year":"2023","journal-title":"Cancer Commun."},{"key":"10.1016\/j.omta.2026.201734_bib15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omta.2026.201734_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201734_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20152008","article-title":"CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia","volume":"214","author":"Riether","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omta.2026.201734_bib18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s12967-024-05101-1","article-title":"The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment","volume":"22","author":"Xiong","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omta.2026.201734_bib19","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201734_bib20","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","article-title":"Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma","volume":"32","author":"Tannir","year":"2014","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.omta.2026.201734_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.07.007","article-title":"CD70: An emerging target in cancer immunotherapy","volume":"155","author":"Jacobs","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.omta.2026.201734_bib22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1517\/14728222.2016.1158812","article-title":"Therapeutic targeting of CD70 and CD27","volume":"20","author":"Wajant","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.omta.2026.201734_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-4939-9170-9_3","article-title":"Rapid quantitative evaluation of CRISPR genome editing by TIDE and TIDER","volume":"1961","author":"Brinkman","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omta.2026.201734_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omta.2026.201734_bib25","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41551-023-01157-4","article-title":"Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair","volume":"8","author":"Webber","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omta.2026.201734_bib26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/gt.2012.97","article-title":"Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase","volume":"20","author":"Jonnalagadda","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201734_bib27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","article-title":"A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers","volume":"13","author":"Wong","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201734_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1388018","article-title":"Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression","volume":"15","author":"Kim","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201734_bib29","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.7150\/thno.79942","article-title":"Cytokine engineered NK-92 therapy to improve persistence and anti-tumor activity","volume":"13","author":"Shin","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.omta.2026.201734_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omta.2026.201734_bib31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-025-02158-2","article-title":"Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation","volume":"10","author":"Luo","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omta.2026.201734_bib32","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201734_bib33","doi-asserted-by":"crossref","first-page":"9421","DOI":"10.1073\/pnas.1300140110","article-title":"Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand","volume":"110","author":"Nakamura","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201734_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.599526","article-title":"Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity","volume":"12","author":"Binder","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201734_bib35","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood.2020006200","article-title":"CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity","volume":"136","author":"Naeimi Kararoudi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201734_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1526379","article-title":"CD8\u03b1 and CD70 mark human natural killer cell populations which differ in cytotoxicity","volume":"16","author":"Rey","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201734_bib37","article-title":"CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omta.2026.201734_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953849","article-title":"Overcoming tumor resistance mechanisms in CAR-NK cell therapy","volume":"13","author":"Valeri","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201734_bib39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5507\/bp.2021.048","article-title":"The high-performance technology CRISPR\/Cas9 improves knowledge and management of acute myeloid leukemia","volume":"165","author":"Mihaila","year":"2021","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub."},{"key":"10.1016\/j.omta.2026.201734_bib40","article-title":"CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity","volume":"12","author":"Hejazi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201734_bib41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-024-01604-y","article-title":"Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia","volume":"17","author":"Sedloev","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omta.2026.201734_bib42","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1158\/2159-8290.CD-24-0096","article-title":"CD28 costimulation augments CAR signaling in NK cells via the LCK\/CD3\u03b6\/ZAP70 signaling axis","volume":"14","author":"Acharya","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omta.2026.201734_bib43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Van den Eynde","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omta.2026.201734_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cells11010021","article-title":"Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing","volume":"11","author":"Branella","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.omta.2026.201734_bib45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omta.2026.201734_bib46","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.exphem.2006.10.018","article-title":"Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells","volume":"35","author":"Kato","year":"2007","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.omta.2026.201734_bib47","article-title":"Non-viral chimeric antigen receptor (CAR) T cells going viral","volume":"18","author":"Balke-Want","year":"2023","journal-title":"Immunooncol. Technol."},{"key":"10.1016\/j.omta.2026.201734_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122683","article-title":"The paths toward non-viral CAR-T cell manufacturing: A comprehensive review of state-of-the-art methods","volume":"348","author":"Metanat","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.omta.2026.201734_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omta.2026.201734_bib50","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","article-title":"CRISPResso2 provides accurate and rapid genome editing sequence analysis","volume":"37","author":"Clement","year":"2019","journal-title":"Nat. Biotechnol."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:41:49Z","timestamp":1782780109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26000698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3117387X26000698"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201734","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficient, fratricide free non-viral engineering of CD70-targeted CAR NK cells for hematologic and solid tumor immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201734","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 University of Minnesota. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201734"}}